×
S&P 500   3,882.71 (+0.98%)
DOW   31,248.63 (+0.68%)
QQQ   292.56 (+1.30%)
AAPL   145.60 (+1.88%)
MSFT   268.62 (+0.91%)
META   168.79 (-0.58%)
GOOGL   2,328.33 (+1.61%)
AMZN   114.36 (+0.03%)
TSLA   722.88 (+3.98%)
NVDA   156.18 (+3.23%)
NIO   22.91 (+9.99%)
BABA   124.09 (+4.17%)
AMD   78.35 (+3.98%)
MU   58.53 (+2.02%)
CGC   2.64 (-0.38%)
T   21.10 (+0.05%)
GE   62.30 (+1.19%)
F   11.46 (+3.62%)
DIS   96.46 (+0.40%)
AMC   12.81 (+1.91%)
PFE   53.30 (+1.04%)
PYPL   73.73 (+0.67%)
NFLX   186.27 (+1.20%)
S&P 500   3,882.71 (+0.98%)
DOW   31,248.63 (+0.68%)
QQQ   292.56 (+1.30%)
AAPL   145.60 (+1.88%)
MSFT   268.62 (+0.91%)
META   168.79 (-0.58%)
GOOGL   2,328.33 (+1.61%)
AMZN   114.36 (+0.03%)
TSLA   722.88 (+3.98%)
NVDA   156.18 (+3.23%)
NIO   22.91 (+9.99%)
BABA   124.09 (+4.17%)
AMD   78.35 (+3.98%)
MU   58.53 (+2.02%)
CGC   2.64 (-0.38%)
T   21.10 (+0.05%)
GE   62.30 (+1.19%)
F   11.46 (+3.62%)
DIS   96.46 (+0.40%)
AMC   12.81 (+1.91%)
PFE   53.30 (+1.04%)
PYPL   73.73 (+0.67%)
NFLX   186.27 (+1.20%)
S&P 500   3,882.71 (+0.98%)
DOW   31,248.63 (+0.68%)
QQQ   292.56 (+1.30%)
AAPL   145.60 (+1.88%)
MSFT   268.62 (+0.91%)
META   168.79 (-0.58%)
GOOGL   2,328.33 (+1.61%)
AMZN   114.36 (+0.03%)
TSLA   722.88 (+3.98%)
NVDA   156.18 (+3.23%)
NIO   22.91 (+9.99%)
BABA   124.09 (+4.17%)
AMD   78.35 (+3.98%)
MU   58.53 (+2.02%)
CGC   2.64 (-0.38%)
T   21.10 (+0.05%)
GE   62.30 (+1.19%)
F   11.46 (+3.62%)
DIS   96.46 (+0.40%)
AMC   12.81 (+1.91%)
PFE   53.30 (+1.04%)
PYPL   73.73 (+0.67%)
NFLX   186.27 (+1.20%)
S&P 500   3,882.71 (+0.98%)
DOW   31,248.63 (+0.68%)
QQQ   292.56 (+1.30%)
AAPL   145.60 (+1.88%)
MSFT   268.62 (+0.91%)
META   168.79 (-0.58%)
GOOGL   2,328.33 (+1.61%)
AMZN   114.36 (+0.03%)
TSLA   722.88 (+3.98%)
NVDA   156.18 (+3.23%)
NIO   22.91 (+9.99%)
BABA   124.09 (+4.17%)
AMD   78.35 (+3.98%)
MU   58.53 (+2.02%)
CGC   2.64 (-0.38%)
T   21.10 (+0.05%)
GE   62.30 (+1.19%)
F   11.46 (+3.62%)
DIS   96.46 (+0.40%)
AMC   12.81 (+1.91%)
PFE   53.30 (+1.04%)
PYPL   73.73 (+0.67%)
NFLX   186.27 (+1.20%)
NASDAQ:ADMA

ADMA Biologics Stock Forecast, Price & News

$2.29
+0.11 (+5.05%)
(As of 07/7/2022 10:15 AM ET)
Add
Compare
Today's Range
$2.14
$2.30
50-Day Range
$1.43
$2.20
52-Week Range
$1.01
$2.32
Volume
39,710 shs
Average Volume
3.53 million shs
Market Capitalization
$448.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.70

ADMA Biologics MarketRank™ Forecast

Analyst Rating
Buy
3.20 Rating Score
Upside/​Downside
147.8% Upside
$5.70 Price Target
Short Interest
Bearish
13.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.29) to ($0.15) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.51 out of 5 stars

Medical Sector

793rd out of 1,433 stocks

Biological Products, Except Diagnostic Industry

124th out of 220 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ADMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter.

ADMA Biologics logo

About ADMA Biologics (NASDAQ:ADMA) Stock

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Stock News Headlines

A Bigger Opportunity For Growth…
A smaller stock with a relatively low market cap often outperforms a larger company stock with a much higher market cap… And when an investor is spending fewer dollars for a stock purchase there’s a bigger opportunity for growth. Click Here for Our Top 5 Microcap Stocks.
Why ADMA Biologics Shares Are Rising Today
ADMA Biologics share price hits a one-year high
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
ADMA Biologics: A Path To Profits Looks Clear
2ADMA : Recap: ADMA Biologics Q1 Earnings
ADMA Biologics Q1 2022 Earnings Preview
Here's what Wall Street expects from ADMA Biologics's earnings
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADMA
Employees
527
Year Founded
N/A

Company Calendar

Last Earnings
5/11/2022
Today
7/07/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$5.70
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+148.9%
Consensus Rating
Buy
Rating Score (0-4)
3.2
Research Coverage
5 Analysts

Profitability

Net Income
$-71,650,000.00
Pretax Margin
-83.27%

Debt

Sales & Book Value

Annual Sales
$80.94 million
Book Value
$0.72 per share

Miscellaneous

Free Float
184,361,000
Market Cap
$448.66 million
Optionable
Optionable
Beta
1.03














ADMA Biologics Frequently Asked Questions

Should I buy or sell ADMA Biologics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ADMA Biologics stock.
View analyst ratings for ADMA Biologics
or view top-rated stocks.

What is ADMA Biologics' stock price forecast for 2022?

5 brokers have issued 12 month target prices for ADMA Biologics' shares. Their ADMA stock forecasts range from $3.00 to $10.00. On average, they anticipate ADMA Biologics' share price to reach $5.70 in the next twelve months. This suggests a possible upside of 161.5% from the stock's current price.
View analysts' price targets for ADMA Biologics
or view top-rated stocks among Wall Street analysts.

How has ADMA Biologics' stock price performed in 2022?

ADMA Biologics' stock was trading at $1.41 at the beginning of 2022. Since then, ADMA shares have increased by 54.6% and is now trading at $2.18.
View the best growth stocks for 2022 here
.

When is ADMA Biologics' next earnings date?

ADMA Biologics is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for ADMA Biologics
.

How were ADMA Biologics' earnings last quarter?

ADMA Biologics, Inc. (NASDAQ:ADMA) released its earnings results on Wednesday, May, 11th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.02. The biotechnology company had revenue of $29.10 million for the quarter, compared to analysts' expectations of $26.50 million. ADMA Biologics had a negative net margin of 83.27% and a negative trailing twelve-month return on equity of 59.36%. During the same period in the prior year, the business earned ($0.16) earnings per share.
View ADMA Biologics' earnings history
.

What guidance has ADMA Biologics issued on next quarter's earnings?

ADMA Biologics issued an update on its FY 2022 earnings guidance on Wednesday, June, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $130.00M-, compared to the consensus revenue estimate of $128.50 million.

Who are ADMA Biologics' key executives?

ADMA Biologics' management team includes the following people:
  • Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 45, Pay $1.39M) (LinkedIn Profile)
  • Dr. Jerrold B. Grossman D.P.S., Ph.D., Co-Founder & Vice Chairman (Age 74, Pay $70.9k)
  • Mr. Brian Lenz CPA, CPA, Exec. VP, CFO & GM of ADMA BioCenters (Age 50, Pay $1.02M) (LinkedIn Profile)
  • Ms. Kaitlin Kestenberg, VP of Compliance, Project Management & Clinical Operations
  • Mr. Michael Goldstein, Sr. Director & Gen. Counsel
  • Mr. Michael Least, VP of Sales & Commercial Operations
  • Mr. Drew Pantello, VP of Marketing & Corp. Devel.
  • Mr. Neal C. Fitzpatrick, VP of Sales
  • Dr. Gene A. Wetzstein BCOP, Pharm.D., Exec. Director & Head of Scientific Engagement
  • Ms. Cyndi Tolman, Sr. VP of Plasma Services

What is Adam S. Grossman's approval rating as ADMA Biologics' CEO?

9 employees have rated ADMA Biologics CEO Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among ADMA Biologics' employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ADMA Biologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), OrganiGram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

How do I buy shares of ADMA Biologics?

Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ADMA Biologics' stock price today?

One share of ADMA stock can currently be purchased for approximately $2.18.

How much money does ADMA Biologics make?

ADMA Biologics (NASDAQ:ADMA) has a market capitalization of $427.11 million and generates $80.94 million in revenue each year. The biotechnology company earns $-71,650,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis.

How many employees does ADMA Biologics have?

ADMA Biologics employs 527 workers across the globe.

How can I contact ADMA Biologics?

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The official website for ADMA Biologics is www.admabiologics.com. The biotechnology company can be reached via phone at (201) 478-5552, via email at info@admabio.com, or via fax at 201-478-5553.

This page (NASDAQ:ADMA) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.